Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement
Combination of Elektrofi’s ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Oct 23
Combination of Elektrofi’s ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in…
25 Oct 23
Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing…
24 Oct 23
The Swiss drugmaker will make an upfront of $7.1bn and a near-term milestone payment of $150m, for rights…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Oct 23
The enlarged company after the subsequent merger is anticipated to operate under the name NAYA Biosciences and will…
24 Oct 23
As per the multi-year agreement, Samsung Biologics will offer Kurma Partners' portfolio companies with customised services for chemistry,…
24 Oct 23
The approval is supported by the safety and efficacy data from the Phase 3 HERO trial of Orgovyx…
24 Oct 23
Certa previously announced positive top-line results from a Phase 2 study which indicated that treatment with FT011 for…
24 Oct 23
The agreement with the direct purchasers will mark the conclusion of the MDL, once the settlements for the…
20 Oct 23
The European Commission has unconditionally approved the transaction, concluding that the proposed transaction would not significantly reduce competition…
20 Oct 23
The expansion project, part of the global investment plans announced in 2022, includes construction of a new extensive…